Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation

BACKGROUND AND OBJECTIVE: Fabry disease (FD) is a rare lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (aGal A). Since 2001, two different enzyme replacement therapies have been authorized, with agalsidase beta being used in most parts of the Western world. Currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kuilenburg, André B. P., Hollak, Carla E. M., Travella, Ana, Jacobs, Melisa, Gentilini, Lucas D., Leen, René, der Vlugt, Karen M. M. Ghauharali-van, Stet, Femke S. Beers, Goorden, Susan M. I., van der Veen, Sanne, Criscuolo, Marcelo, Papouchado, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293523/
https://www.ncbi.nlm.nih.gov/pubmed/37083901
http://dx.doi.org/10.1007/s40268-023-00421-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293523/
https://www.ncbi.nlm.nih.gov/pubmed/37083901
http://dx.doi.org/10.1007/s40268-023-00421-x

Ejemplares similares